G. K. Hansson and A. Hermansson, The immune system in atherosclerosis, Nature Immunology, vol.12, issue.3, pp.204-212, 2011.

G. Caiazzo, G. Fabbrocini, R. Di-caprio, A. Raimondo, E. Scala et al., Psoriasis, Cardiovascular Events, and Biologics: Lights and Shadows, Frontiers in Immunology, vol.9, p.1668, 2018.

P. M. Ridker, Anticytokine Agents, Circulation Research, vol.124, issue.3, pp.437-450, 2019.

Y. A. Elnabawi, A. K. Dey, A. Goyal, J. W. Groenendyk, J. H. Chung et al., Coronary artery plaque characteristics and treatment with biologic therapy in severe psoriasis: results from a prospective observational study, Cardiovascular Research, vol.115, issue.4, pp.721-728, 2019.

A. V. Sorokin, K. Kotani, Y. A. Elnabawi, A. K. Dey, A. P. Sajja et al., Association Between Oxidation-Modified Lipoproteins and Coronary Plaque in Psoriasis, Circulation Research, vol.123, issue.11, pp.1244-1254, 2018.

S. K. Mahil, F. Capon, and J. N. Barker, Update on psoriasis immunopathogenesis and targeted immunotherapy, Seminars in Immunopathology, vol.38, issue.1, pp.11-27, 2015.

N. N. Mehta, D. B. Shin, A. A. Joshi, A. K. Dey, A. W. Armstrong et al., Effect of 2 Psoriasis Treatments on Vascular Inflammation and Novel Inflammatory Cardiovascular Biomarkers, Circulation: Cardiovascular Imaging, vol.11, issue.6, p.7394, 2018.

J. M. Gelfand, D. B. Shin, A. Alavi, D. A. Torigian, T. Werner et al., A Phase IV, Randomized, Double-Blind, Placebo-Controlled Crossover Study of the Effects of Ustekinumab on Vascular Inflammation in Psoriasis (the VIP-U Trial), Journal of Investigative Dermatology, vol.140, issue.1, pp.85-93.e2, 2020.

I. Y. Iskandar, D. M. Ashcroft, R. B. Warren, M. Lunt, K. Mcelhone et al., Comparative effectiveness of biological therapies on improvements in quality of life in patients with psoriasis, British Journal of Dermatology, vol.177, issue.5, pp.1410-1421, 2017.

E. Sbidian, A. Chaimani, and I. Garcia-doval, Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev, vol.12, p.11535, 2017.

D. Minno, M. Iervolino, S. Peluso, R. Scarpa, R. et al., CaRRDs study group. Carotid intimamedia thickness in psoriatic arthritis: differences between tumor necrosis factor-? blockers and traditional disease-modifying antirheumatic drugs, Arterioscler Thromb Vasc Biol, vol.31, issue.3, pp.705-712, 2011.

J. J. Wu, A. Guérin, M. Sundaram, K. Dea, M. Cloutier et al., Cardiovascular event risk assessment in psoriasis patients treated with tumor necrosis factor-? inhibitors versus methotrexate, Journal of the American Academy of Dermatology, vol.76, issue.1, pp.81-90, 2017.

A. S. Low, D. P. Symmons, M. Lunt, L. K. Mercer, C. P. Gale et al., Relationship between exposure to tumour necrosis factor inhibitor therapy and incidence and severity of myocardial infarction in patients with rheumatoid arthritis, Annals of the Rheumatic Diseases, vol.76, issue.4, pp.654-660, 2017.

M. Canault, F. Peiretti, and C. Mueller, Exclusive expression of transmembrane TNF-? in mice reduces the inflammatory response in early lipid lesions of aortic sinus, Atherosclerosis, vol.172, issue.2, pp.211-218, 2004.

C. Ryan, Y. Daoud, and A. Menter, Biologic Therapies for Chronic Plaque Psoriasis and Cardiovascular Events?Reply, JAMA, vol.306, issue.19, p.1196, 2011.

T. Tzellos, A. Kyrgidis, and C. C. Zouboulis, Re-evaluation of the risk for major adverse cardiovascular events in patients treated with anti-IL-12/23 biological agents for chronic plaque psoriasis: a meta-analysis of randomized controlled trials, Journal of the European Academy of Dermatology and Venereology, vol.27, issue.5, pp.622-627, 2012.

E. D. Dommasch, A. B. Troxel, and J. M. Gelfand, Major cardiovascular events associated with anti-IL 12/23 agents: A tale of two meta-analyses, Journal of the American Academy of Dermatology, vol.68, issue.5, pp.863-865, 2013.

T. Tzellos, A. Kyrgidis, A. Trigoni, and C. C. Zouboulis, Association of anti-IL-12/23 biologic agents ustekinumab and briakinumab with major adverse cardiovascular events, Journal of the European Academy of Dermatology and Venereology, vol.27, issue.12, pp.1586-1587, 2013.

S. Taleb, M. Romain, B. Ramkhelawon, C. Uyttenhove, G. Pasterkamp et al., Loss of SOCS3 expression in T cells reveals a regulatory role for interleukin-17 in atherosclerosis, Journal of Experimental Medicine, vol.206, issue.10, pp.2067-2077, 2009.

A. Gisterå, A. Robertson, J. Andersson, D. F. Ketelhuth, O. Ovchinnikova et al., Transforming Growth Factor?? Signaling in T Cells Promotes Stabilization of Atherosclerotic Plaques Through an Interleukin-17?Dependent Pathway, Science Translational Medicine, vol.5, issue.196, pp.196ra100-196ra100, 2013.

S. Taleb, A. Tedgui, and Z. Mallat, IL-17 and Th17 Cells in Atherosclerosis, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.35, issue.2, pp.258-264, 2015.

A. R. Fatkhullina, I. O. Peshkova, A. Dzutsev, T. Aghayev, J. A. Mcculloch et al., An Interleukin-23-Interleukin-22 Axis Regulates Intestinal Microbial Homeostasis to Protect from Diet-Induced Atherosclerosis, Immunity, vol.49, issue.5, pp.943-957.e9, 2018.

P. Tuppin, J. Rudant, P. Constantinou, C. Gastaldi-ménager, A. Rachas et al., Value of a national administrative database to guide public decisions: From the système national d?information interrégimes de l?Assurance Maladie (SNIIRAM) to the système national des données de santé (SNDS) in France, Revue d'Épidémiologie et de Santé Publique, vol.65, issue.4, pp.S149-S167, 2017.

S. Suissa, The Case-Time-Control Design, Epidemiology, vol.9, issue.4, pp.441-445, 1998.

M. Maclure, The Case-Crossover Design: A Method for Studying Transient Effects on the Risk of Acute Events, American Journal of Epidemiology, vol.133, issue.2, pp.144-153, 1991.

G. P. Consiglio, A. M. Burden, M. Maclure, L. Mccarthy, and S. M. Cadarette, Case-crossover study design in pharmacoepidemiology: systematic review and recommendations, Pharmacoepidemiology and Drug Safety, vol.22, issue.11, pp.1146-1153, 2013.

S. Suissa, THE CASE-TIME-CONTROL DESIGN, Epidemiology, vol.6, issue.3, pp.248-253, 1995.

S. Greenland, Basic problems in interaction assessment., Environmental Health Perspectives, vol.101, issue.suppl 4, pp.59-66, 1993.

S. Selvin, Statistical Analysis of Epidemiologic Data, 2004.

K. Reich, R. G. Langley, M. Lebwohl, P. Szapary, C. Guzzo et al., Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies, British Journal of Dermatology, vol.164, issue.4, pp.862-872, 2011.

W. Rungapiromnan, Z. Z. Yiu, R. B. Warren, C. E. Griffiths, and D. M. Ashcroft, Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta-analysis of randomized controlled trials, British Journal of Dermatology, vol.176, issue.4, pp.890-901, 2017.

H. Ait-oufella, A. P. Sage, Z. Mallat, and A. Tedgui, Adaptive (T and B Cells) Immunity and Control by Dendritic Cells in Atherosclerosis, Circulation Research, vol.114, issue.10, pp.1640-1660, 2014.

K. Danzaki, Y. Matsui, M. Ikesue, D. Ohta, K. Ito et al., Interleukin-17A Deficiency Accelerates Unstable Atherosclerotic Plaque Formation in Apolipoprotein E-Deficient Mice, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.32, issue.2, pp.273-280, 2012.

G. Allam, A. Abdel-moneim, and A. M. Gaber, The pleiotropic role of interleukin-17 in atherosclerosis, Biomedicine & Pharmacotherapy, vol.106, pp.1412-1418, 2018.

T. Simon, S. Taleb, N. Danchin, L. Laurans, B. Rousseau et al., Circulating levels of interleukin-17 and cardiovascular outcomes in patients with acute myocardial infarction, European Heart Journal, vol.34, issue.8, pp.570-577, 2012.

O. Ahlehoff, L. Skov, G. Gislason, R. Gniadecki, L. Iversen et al., Cardiovascular outcomes and systemic anti-inflammatory drugs in patients with severe psoriasis: 5-year follow-up of a Danish nationwide cohort, Journal of the European Academy of Dermatology and Venereology, vol.29, issue.6, pp.1128-1134, 2014.

K. Reich, U. Mrowietz, M. A. Radtke, D. Thaci, S. J. Rustenbach et al., Drug safety of systemic treatments for psoriasis: results from The German Psoriasis Registry PsoBest, Archives of Dermatological Research, vol.307, issue.10, pp.875-883, 2015.

M. P. Lee, R. J. Desai, Y. Jin, G. Brill, A. Ogdie et al., Association of Ustekinumab vs TNF Inhibitor Therapy With Risk of Atrial Fibrillation and Cardiovascular Events in Patients With Psoriasis or Psoriatic Arthritis, JAMA Dermatology, vol.155, issue.6, p.700, 2019.

P. S. Wang, S. Schneeweiss, R. J. Glynn, H. Mogun, and J. Avorn, Use of the case-crossover design to study prolonged drug exposures and insidious outcomes, Annals of Epidemiology, vol.14, issue.4, pp.296-303, 2004.

M. L. Bots, M. K. Palmer, S. Dogan, Y. Plantinga, J. S. Raichlen et al., Intensive lipid lowering may reduce progression of carotid atherosclerosis within 12 months of treatment: the METEOR study, Journal of Internal Medicine, vol.265, issue.6, pp.698-707, 2009.

A. A. Joshi, J. B. Lerman, A. K. Dey, A. P. Sajja, A. D. Belur et al., Association Between Aortic Vascular Inflammation and Coronary Artery Plaque Characteristics in Psoriasis, JAMA Cardiology, vol.3, issue.10, p.949, 2018.